You are viewing a free summary from Descrybe.ai. For citation checking, legal issue analysis, and other advanced tools, explore our Legal Research Toolkit — not free, but close.

Stanton J. Rowe v. Michael Dror and Paul Trescony

Citations: 112 F.3d 473; 42 U.S.P.Q. 2d (BNA) 1550; 1997 U.S. App. LEXIS 7911Docket: 96-1304

Court: Court of Appeals for the Federal Circuit; April 21, 1997; Federal Appellate Court

Narrative Opinion Summary

The case involves an appeal by the applicant of a patent application concerning balloon angioplasty catheters, which was contested in an interference proceeding declared by the Patent and Trademark Office (PTO). The interference was between Rowe's application, assigned to Cordis Corp., and an issued patent held by Dror and Trescony, assigned to Medtronic, Inc. The PTO Board previously ruled that Rowe's claims were anticipated by the Lemelson patent, which did not specifically disclose a balloon angioplasty catheter. Rowe appealed, arguing that the Board incorrectly construed the preamble 'balloon angioplasty catheter' as non-limiting and thus erred in its anticipation finding. The court agreed, emphasizing that the preamble provided a structural limitation when interpreted in the context of Rowe's specifications, which distinguished his invention from general-purpose catheters. Consequently, the court reversed and remanded the Board's decision, asserting that the Lemelson patent did not disclose every limitation of Rowe's claims. The court's decision stressed the need for precise interpretation of claim terms and recognized the Jepson claim format's role in defining invention scope. Both parties were directed to bear their own costs, and the case was sent back to the PTO for further proceedings.

Legal Issues Addressed

Anticipation under Patent Law

Application: The court found that the Board erred in its determination that the Lemelson patent anticipated Rowe's claims related to balloon angioplasty catheters.

Reasoning: The court determined that the Board erred in this anticipation finding, leading to a reversal and remand of the decision.

Broadest Reasonable Interpretation Standard

Application: The court underscored the necessity for claim terms to be interpreted with their broadest reasonable meaning, as evidenced by the interpretation of 'balloon angioplasty catheter.'

Reasoning: The patent examination process mandates that claims are interpreted with their broadest reasonable meaning, while also examining the entire patent to understand claim terms.

Interpretation of Claim Preambles

Application: The court evaluated the significance of the term 'balloon angioplasty catheter' in the claim preamble, ultimately determining that 'angioplasty' served as a structural limitation.

Reasoning: The significance of a claim preamble is determined by its contextual meaning within the claim as a whole. If the preamble defines structural limitations, it is treated as such; if it merely states purpose or use, it is not a limitation.

Jepson Claim Format

Application: The court recognized Rowe’s use of the Jepson claim format to define the structural limitations of his invention related to balloon angioplasty catheters.

Reasoning: The Jepson form permits a patentee to include known elements in the preamble of a claim, which helps define both context and scope.

Patent Interference Proceedings

Application: Rowe's appeal centered on the PTO's interference proceeding, where the Board failed to individually assess each of Rowe’s claims for patentability against the Lemelson patent.

Reasoning: The PTO has the authority during an interference to determine the patentability of any claim involved, and it must assess each claim separately for patentability.